Page 1056 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

determinant of survival in human septic shock. Crit Care Med. transplantation: a 6-year retrospective study. Bone Marrow
2006;34(6):1589-1596. Transplant. November 2005;36(10):879-883.
56. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery 72. Maschmeyer G, Patterson TF. New immunosuppressive agents
and appropriate antibiotic selection reduce length of hospital and risk for invasive fungal infections. Curr Infect Dis Rep.
stay of patients with community-acquired pneumonia: link November 2009;11(6):435-438.
between quality of care and resource utilization. Arch Intern 73. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL,
Med. March 25 2002;162(6):682-688. Montori V. Anti-TNF antibody therapy in rheumatoid arthritis
57. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of and the risk of serious infections and malignancies: systematic
antibiotic administration and outcomes for Medicare patients review and meta-analysis of rare harmful effects in randomized
hospitalized with community-acquired pneumonia. Arch Intern controlled trials. JAMA. May 17, 2006;295(19):2275-2285.
Med. March 22, 2004;164(6):637-644. 74. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with
58. Perrone J, Hollander JE, Datner EM. Emergency Department infliximab, a tumor necrosis factor alpha-neutralizing agent.
evaluation of patients with fever and chemotherapy-induced N Engl J Med. October 11, 2001;345(15):1098-1104.
neutropenia. J Emerg Med. August 2004;27(2):115-119. 75. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous
59. Richardson S, Pallot D, Hughes T, Littlewood T. Improving infections due to tumor necrosis factor blockade: correction.
management of neutropenic sepsis in the emergency depart- Clin Infect Dis. October 15, 2004;39(8):1254-1255.
ment. Br J Haematol. February 2009;144(4):617-618. 76. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal
60. Courtney DM, Aldeen AZ, Gorman SM, et al. Cancer- infections complicating tumor necrosis factor alpha blockade
associated neutropenic fever: clinical outcome and economic therapy. Mayo Clin Proc. 2008;83(2):181-194.
costs of emergency department care. Oncologist. August 77. Docke WD, Prosch S, Fietze E, et al. Cytomegalovirus reac-
2007;12(8):1019-1026. tivation and tumour necrosis factor. Lancet. January 29,
61. Szwajcer D, Czaykowski P, Turner D. Assessment and manage- 1994;343(8892):268-269.
ment of febrile neutropenia in emergency departments within 78. Fietze E, Prosch S, Reinke P, et al. Cytomegalovirus infec-
a regional health authority-a benchmark analysis. Curr Oncol. tion in transplant recipients: the role of tumor necrosis factor.
December 2011;18(6):280-284. Transplantation. September 27, 1994;58(6):675-680.
62. Okera M, Chan S, Dernede U, et al. A prospective study of 79. Issa NC, Fishman JA. Infectious complications of antilympho-
chemotherapy-induced febrile neutropenia in the South West cyte therapies in solid organ transplantation. Clin Infect Dis.
London Cancer Network. Interpretation of study results in March 15, 2009;48(6):772-786.
light of NCAG/NCEPOD findings. Br J Cancer. February 1
2011;104(3):407-412. 80. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-
associated nephropathy in renal transplantation: interdisciplinary
63. Amado VM, Vilela GP, Queiroz A Jr, Amaral AC. Effect of a analyses and recommendations. Transplantation. May 27, 2005;
quality improvement intervention to decrease delays in antibi- 79(10):1277-1286.
otic delivery in pediatric febrile neutropenia: a pilot study. J Crit
Care. February 2011;26(1):103. e109-112. 81. Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and
marrow transplant recipients. Bone Marrow Transplant. January
64. Nirenberg A, Mulhearn L, Lin S, Larson E. Emergency depart- 2008;41(1):11-18.
ment waiting times for patients with cancer with febrile neutro-
penia: a pilot study. Oncol Nurs Forum. July 2004;31(4):711-715. 82. Koo S, Marty FM, Baden LR. Infectious complications associ-
ated with immunomodulating biologic agents. Infect Dis Clin
65. Freifeld A, Bow EJ, Sepkowitz KA, et al. Clinical practice North Am. June 2010;24(2):285-306.
guideline for the use of antimicrobial agents in neutropenic
patients with cancer: 2010 update by the Infectious Diseases 83. Morris EC, Rebello P, Thomson KJ, et al. Pharmacokinetics
Society of America. Clin Infect Dis: Infectious Diseases Society of alemtuzumab used for in vivo and in vitro T-cell depletion
of America; 2011;52(4):e56-e93. in allogeneic transplantations: relevance for early adoptive
immunotherapy and infectious complications. Blood. July 1,
66. Dupuy JM, Kourilsky FM, Fradelizzi D, et al. Depression of 2003;102(1):404-406.
immunologic reactivity of patients with acute leukemia. Cancer.
1971;27(2):323-331. 84. Koo S, Baden LR. Infectious complications associated with
immunomodulating monoclonal antibodies used in the treat-
67. Hersh EM, Gutterman JU, Mavligit GM, et al. Serial studies of ment of hematologic malignancy. J Natl Compr Canc Netw.
immunocompetence of patients undergoing chemotherapy for 2008;6(2):202-213.
acute leukemia. J Clin Invest. 1974;54(2):401-408.
85. Park SH, Choi SM, Lee DG, et al. Infectious complications asso-
68. Morrison VA. Infectious complications of chronic lympho- ciated with alemtuzumab use for allogeneic hematopoietic stem
cytic leukaemia: pathogenesis, spectrum of infection, pre- cell transplantation: comparison with anti-thymocyte globulin.
ventive approaches. Best Pract Res Clin Haematol. March Transpl Infect Dis. October 2009;11(5):413-423.
2010;23(1):145-153.
86. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious
69. Kovacs JA, Masur H. Evolving health effects of Pneumocystis: complications of monoclonal antibodies used in cancer therapy:
one hundred years of progress in diagnosis and treatment. a systematic review of the evidence from randomized controlled
JAMA. June 24, 2009;301(24):2578-2585. trials. Cancer. 2007;109(11):2182-2189.
70. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J 87. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab mainte-
Med. June 10, 2004;350(24):2487-2498. nance for the treatment of patients with follicular lymphoma:
71. De Castro N, Neuville S, Sarfati C, et al. Occurrence of systematic review and meta-analysis of randomized trials. J Natl
Pneumocystis jiroveci pneumonia after allogeneic stem cell Cancer Inst. February 18, 2009;101(4):248-255.

Section05-O-ref.indd 3 1/20/2015 4:51:19 PM